Omeros CorpNASDAQ:OMER
- LAST PRICE6.4600
- TODAY'S CHANGE (%)-0.2900 (-4.2963%)
- Bid / Lots6.4600/ 8
- Ask / Lots6.5100/ 8
- Open / Previous Close6.7500 / 6.7500
- Day Range
- 52 Week Range
- Volume497,519
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OMER |
|---|---|---|
| 09:32 ET | 24765 | 6.65 |
| 09:33 ET | 17563 | 6.575 |
| 09:35 ET | 43346 | 6.54 |
| 09:37 ET | 5046 | 6.545 |
| 09:39 ET | 1412 | 6.578 |
| 09:42 ET | 9734 | 6.55 |
| 09:44 ET | 15113 | 6.44 |
| 09:46 ET | 4874 | 6.4 |
| 09:48 ET | 3133 | 6.486 |
| 09:50 ET | 3087 | 6.505 |
| 09:51 ET | 3004 | 6.43 |
| 09:53 ET | 4932 | 6.41 |
| 09:55 ET | 326539 | 6.44 |
| 09:57 ET | 1866 | 6.4 |
| 10:00 ET | 1074 | 6.49 |
| 10:02 ET | 1805 | 6.49 |
| 10:04 ET | 2000 | 6.53 |
| 10:06 ET | 215 | 6.54 |
| 10:08 ET | 5939 | 6.51 |
| 10:09 ET | 2006 | 6.47 |
| 10:11 ET | 300 | 6.46 |
Nov 14, 2024
DJ Omeros Shares Hit 52-Week High on Plan to Resubmit Narsoplimab Application, from 1:33PM ET on Thursday Nov 14, 2024 by Dow Jones
1:33PM ET on Thursday Nov 14, 2024 by Dow JonesDJ Omeros Up Over 49%, On Pace for Largest Percent Increase Since February 2023 -- Data Talk, from 11:25AM ET on Thursday Nov 14, 2024 by Dow Jones
11:25AM ET on Thursday Nov 14, 2024 by Dow JonesDJ Omeros Initiated at Buy by Rodman & Renshaw, from 7:04AM ET on Thursday Nov 14, 2024 by Dow Jones
7:04AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 13, 2024
Omeros Corporation Reports Third Quarter 2024 Financial Results, from 4:02PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:02PM ET on Wednesday Nov 13, 2024 by Dow Jones*DJ Omeros 3Q Loss/Shr 56c >OMER, from 4:02PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:02PM ET on Wednesday Nov 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Omeros Corp | 391.1M | -2.1x | --- |
Prime Medicine Inc | 401.5M | -1.6x | --- |
Q32 Bio Inc | 401.4M | -4.5x | --- |
Larimar Therapeutics Inc | 426.9M | -5.4x | --- |
Northwest Biotherapeutics Inc | 365.9M | -4.6x | --- |
Lexicon Pharmaceuticals Inc | 352.5M | -1.3x | --- |
Company Information
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Contact Information
- Headquarters
- 201 Elliott Avenue WestSEATTLE, WA, United States 98119
- Phone
- 206-676-5000
- Fax
- 206-676-5005
Executives
- Chairman of the Board, President, Chief Executive Officer
- Gregory Demopulos
- Chief Accounting Officer, Vice President - Finance, Treasurer
- David Borges
- Vice President - Science, Chief Scientific Officer
- George Gaitanaris
- Vice President, General Counsel, Secretary
- Peter Cancelmo
- Vice President - Human Resources
- Peter Williams
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $391.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 57.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.56 |
EPS | $-3.14 |
Book Value | $-0.41 |
P/E Ratio | -2.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
